Psychosocial Intervention in Latino Patients With Advanced Cancer

September 11, 2023 updated by: University of Colorado, Denver

Expanding the Reach of Palliative Care: Pilot Study of a Psychosocial Intervention in Latino Patients With Advanced Cancer

Palliative Care focuses on symptom management and quality of life and helps patients with life-limiting illness match goals and preferences for care. While there has been interest in and acknowledgement that palliative care is an important part of training patient navigators, there have been no previous studies examining the effectiveness of a navigation intervention to improve palliative care for patients. This study will examine the feasibility to implement patient navigator and psychosocial interventions.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Aurora, Colorado, United States, 80218
        • University of Colorado

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults ages > or = 18 years of age
  • Must self-identify as Latino/a
  • Have stage III/IV cancer
  • Seeking or In treatment for their cancer (ie: not in hospice care)
  • Not incarcerated
  • Have at least moderate baseline distress (> 4 on the NCCN Distress Thermometer) or positive screen for depression (PHQ-2 score >=3) or anxiety (GAD-2 score >=3)

Exclusion Criteria:

-No exclusion criteria listed

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Stepped Interventions
Patient navigation intervention, plus various psychosocial interventions
The patient navigator will provide educational materials, assessments, and counseling to the patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of Recruitment: number of patients that are eligible to participate
Time Frame: Start of study to end of study, up to 12 months
Assess how likely patients are to join the study through tracking the number of patients that are eligible to participate.
Start of study to end of study, up to 12 months
Feasibility of Completion: number of patients that complete the study
Time Frame: Start of study to end of study, up to 12 months
Assess how likely patients are to adhere to the study through tracking the number of patients that complete the study.
Start of study to end of study, up to 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Process Measure Assessment
Time Frame: Start of study to end of study, up to 12 months
Use the Advance Care Planning Engagement Survey to assess Behavior. 9 item questionnaire based on Change Theory using a 6 point Likert scale. Total score is a mean of all items with a range of 1-6.
Start of study to end of study, up to 12 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
FACT-G Quality of Life Assessment
Time Frame: Start of study to end of study, up to 12 months
Assess each patient's quality of life through the Function Assessment of Chronic Illness Therapy-General (FACT-G), which is a 27 question self-reporting measure of quality of life. Scale range is 0-108, higher scores indicating higher quality of life.
Start of study to end of study, up to 12 months
Depression Assessment
Time Frame: Start of study to end of study, up to 12 months
Use the Patient Health Questionnaire-8 to measure depressive symptoms through an 8 item assessment. Score ranges are 0-24, higher scores representing more depressive symptoms.
Start of study to end of study, up to 12 months
Anxiety Assessment
Time Frame: Start of study to end of study, up to 12 months
Use the Generalize Anxiety Disorder-7 to measure symptoms of anxiety through a 7 question assessment. Score range is 0-21, with increased scores representing higher levels of anxiety.
Start of study to end of study, up to 12 months
Pain Assessment: PEG questionnaire
Time Frame: Start of study to end of study, up to 12 months
The PEG questionnaire assesses pain intensity and interference on a numeric rating scale. Scale range of each of three items is 0-10. Total score is the mean of the three item scores.
Start of study to end of study, up to 12 months
Symptom Severity Assessment
Time Frame: Start of study to end of study, up to 12 months
Use the Edmonton Symptom Assessment Scale (ESAS-r) to assess symptom severity on a numeric rating scale. Score range for each of the 9 items is 0-10 with total score summary of all individual symptom items.
Start of study to end of study, up to 12 months
Hospital Assessments
Time Frame: Start of study to end of study, up to 12 months
Evaluate the frequency of hospitalizations or deaths through patient medical records
Start of study to end of study, up to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stacy Fischer, MD, University of Colorado, Denver
  • Principal Investigator: David Bekelman, MD, University of Colorado, Denver

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 23, 2018

Primary Completion (Actual)

July 31, 2018

Study Completion (Estimated)

July 1, 2024

Study Registration Dates

First Submitted

November 30, 2018

First Submitted That Met QC Criteria

December 3, 2018

First Posted (Actual)

December 4, 2018

Study Record Updates

Last Update Posted (Actual)

September 13, 2023

Last Update Submitted That Met QC Criteria

September 11, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 17-1955.cc

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Advanced Cancer

Clinical Trials on Counseling

3
Subscribe